Resource impact statement
Cancer Drugs Fund technology
NICE has recommended daratumumab plus bortezomib plus dexamethasone for use within the Cancer Drugs Fund for treating previously treated multiple myeloma.
Daratumumab will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and Janssen-Cilag have a commercial access agreement that makes daratumumab available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.
The resource impact of daratumumab with bortezomib and dexamethasone will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date the managed access agreement expires (January 2021) or when the results of the managed access agreement data collection are available, whichever is sooner. The aim of the review is to decide whether the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.
It is estimated that around 2,700 people per year with multiple myeloma who have received at least one prior therapy are eligible for treatment with daratumumab with bortezomib and dexamethasone.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: 10 April 2019